FDA Panelists Unanimously Back Eli Lilly’s Biogen-Rivaling Alzheimer’s Drug
Investor's Business DailyEli Lilly stock jumped Monday after FDA advisors said the benefits of Alzheimer’s treatment donanemab outweigh the risks for most patients.
The post FDA Panelists Unanimously Back Eli Lilly's Biogen-Rivaling Alzheimer's Drug appeared first on…